Therefore, the combined use of DNAM-1-CD3ζ engineered NK cells with Nutlin-3a in tumors that retain p53-wt, such as most forms of NB, with the exception of some cases of relapse (74), may represent a novel therapeutic approach for solid tumors. Here, CD226 is linked to neuroblastoma.